Literature DB >> 12525998

Pulmonary hypertension associated with connective tissue disease.

Karen A Fagan1, David B Badesch.   

Abstract

Pulmonary arterial hypertension is a life threatening complication of several connective tissue diseases including scleroderma (both diffuse and limited scleroderma, or the CREST syndrome--calcinosis cutis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangectasia), systemic lupus erythomatosis (SLE), mixed connective tissue disease (MCTD), and less commonly, rheumatoid arthritis (RA) and dermatomyositis/polymyositis. This report reviews the occurrence of this complication, potential etiologies, clinical presentation, and treatment options. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12525998     DOI： 10.1053/pcad.2002.129975

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN： 0033-0620            Impact factor:   8.194


  19 in total

1.  Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy.

Authors:  Masashi Ikutani; Koichi Tsuneyama; Makoto Kawaguchi; Junya Fukuoka; Fujimi Kudo; Susumu Nakae; Makoto Arita; Yoshinori Nagai; Satoshi Takaki; Kiyoshi Takatsu
Journal:  JCI Insight       Date:  2017-04-06

2.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

3.  Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension.

Authors:  Michael G Risbano; Christina A Meadows; Christopher D Coldren; Tiffany J Jenkins; Michael G Edwards; David Collier; Wendy Huber; Douglas G Mack; Andrew P Fontenot; Mark W Geraci; Todd M Bull
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

Review 4.  State-of-the-Art Imaging of the Lung for Connective Tissue Disease (CTD).

Authors:  Yoshiharu Ohno; Hisanobu Koyama; Takeshi Yoshikawa; Shinichiro Seki
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

5.  An atypical presentation of adult-onset Still's disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature.

Authors:  Mili V Mehta; Daniel K Manson; Evelyn M Horn; Jennifer Haythe
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

6.  An unexpected diagnosis in a dyspnoeic patient with primary Sjogren syndrome.

Authors:  Ali Raza Rajani; Kosar Hussain; Fahad Omar Baslaib; Kabad N S Rao
Journal:  BMJ Case Rep       Date:  2013-01-17

7.  Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  Reda E Girgis; Adaani E Frost; Nicholas S Hill; Evelyn M Horn; David Langleben; Vallerie V McLaughlin; Ronald J Oudiz; Ivan M Robbins; James R Seibold; Shelley Shapiro; Victor F Tapson; Robyn J Barst
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

8.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

9.  Identification of candidate genes in scleroderma-related pulmonary arterial hypertension.

Authors:  Dmitry N Grigoryev; Stephen C Mathai; Micah R Fisher; Reda E Girgis; Ari L Zaiman; Traci Housten-Harris; Christopher Cheadle; Li Gao; Laura K Hummers; Hunter C Champion; Joe G N Garcia; Fredrick M Wigley; Rubin M Tuder; Kathleen C Barnes; Paul M Hassoun
Journal:  Transl Res       Date:  2008-02-01       Impact factor: 7.012

Review 10.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.